生物技术公司BioNTech(BNTX.US)周一盘中股价大跌6.21%,引发了市场的广泛关注。
消息显示,竞争对手莫德纳公司因新冠疫苗和RSV疫苗需求疲软而下调了2025年的销售预期,预计年收入为15亿至25亿美元,低于此前的25亿至35亿美元预期。市场分析人士认为,这将影响BioNTech的业绩表现。
目前全球新冠疫苗需求正在放缓,同时BioNTech的RSV疫苗也尚未获批上市。分析师预期,公司未来几个季度的营收可能将遭受冲击。另一方面,公司正在积极开发新产品以促进业绩增长,如新冠联合疫苗和流感疫苗。但这些新产品的销售前景仍有待观察。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.